897 related articles for article (PubMed ID: 30181299)
1. Discovery of the IL-23/IL-17 Signaling Pathway and the Treatment of Psoriasis.
Hawkes JE; Yan BY; Chan TC; Krueger JG
J Immunol; 2018 Sep; 201(6):1605-1613. PubMed ID: 30181299
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of emerging immunotherapies in psoriasis.
Yiu ZZ; Warren RB
Immunotherapy; 2015; 7(2):119-33. PubMed ID: 25713988
[TBL] [Abstract][Full Text] [Related]
3. Psoriasis pathogenesis and the development of novel targeted immune therapies.
Hawkes JE; Chan TC; Krueger JG
J Allergy Clin Immunol; 2017 Sep; 140(3):645-653. PubMed ID: 28887948
[TBL] [Abstract][Full Text] [Related]
4. A systematic review and meta-analysis of the efficacy and safety of the interleukin (IL)-12/23 and IL-17 inhibitors ustekinumab, secukinumab, ixekizumab, brodalumab, guselkumab and tildrakizumab for the treatment of moderate to severe plaque psoriasis.
Bilal J; Berlinberg A; Bhattacharjee S; Trost J; Riaz IB; Kurtzman DJB
J Dermatolog Treat; 2018 Sep; 29(6):569-578. PubMed ID: 29532693
[TBL] [Abstract][Full Text] [Related]
5. Monoclonal antibodies inhibiting IL-12, -23, and -17 for the treatment of psoriasis.
Jeon C; Sekhon S; Yan D; Afifi L; Nakamura M; Bhutani T
Hum Vaccin Immunother; 2017 Oct; 13(10):2247-2259. PubMed ID: 28825875
[TBL] [Abstract][Full Text] [Related]
6. New biologics in psoriasis: an update on IL-23 and IL-17 inhibitors.
Dong J; Goldenberg G
Cutis; 2017 Feb; 99(2):123-127. PubMed ID: 28319618
[TBL] [Abstract][Full Text] [Related]
7. Biologic Therapy in Psoriasis (Part II): Efficacy and Safety of New Treatment Targeting IL23/IL-17 Pathways.
Molinelli E; Campanati A; Brisigotti V; Offidani A
Curr Pharm Biotechnol; 2017; 18(12):964-978. PubMed ID: 29299984
[TBL] [Abstract][Full Text] [Related]
8. IL-17 for therapy.
Kurschus FC; Moos S
J Dermatol Sci; 2017 Sep; 87(3):221-227. PubMed ID: 28633806
[TBL] [Abstract][Full Text] [Related]
9. Systematic review of interleukin-12, interleukin-17, and interleukin-23 pathway inhibitors for the treatment of moderate-to-severe chronic plaque psoriasis: ustekinumab, briakinumab, tildrakizumab, guselkumab, secukinumab, ixekizumab, and brodalumab.
Tausend W; Downing C; Tyring S
J Cutan Med Surg; 2014; 18(3):156-69. PubMed ID: 24800703
[TBL] [Abstract][Full Text] [Related]
10. Pathogenic role of IL-17 in psoriasis and psoriatic arthritis.
Chiricozzi A
Actas Dermosifiliogr; 2014 Oct; 105 Suppl 1():9-20. PubMed ID: 25398488
[TBL] [Abstract][Full Text] [Related]
11. Guselkumab (an IL-23-specific mAb) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasis.
Sofen H; Smith S; Matheson RT; Leonardi CL; Calderon C; Brodmerkel C; Li K; Campbell K; Marciniak SJ; Wasfi Y; Wang Y; Szapary P; Krueger JG
J Allergy Clin Immunol; 2014 Apr; 133(4):1032-40. PubMed ID: 24679469
[TBL] [Abstract][Full Text] [Related]
12. Interleukin-17 and innate immunity in infections and chronic inflammation.
Isailovic N; Daigo K; Mantovani A; Selmi C
J Autoimmun; 2015 Jun; 60():1-11. PubMed ID: 25998834
[TBL] [Abstract][Full Text] [Related]
13. Safety of biologics in psoriasis.
Kamata M; Tada Y
J Dermatol; 2018 Mar; 45(3):279-286. PubMed ID: 29226369
[TBL] [Abstract][Full Text] [Related]
14. Characterization of psoriasiform dermatitis induced by systemic injection of interleukin-23 minicircles in mice.
Leys L; Wang Y; Paulsboe S; Edelmayer R; Salte K; Wetter J; Namovic M; Phillips L; Dunstan R; Gauvin D; Donnelly-Roberts D; Su Z; Honore P; McGaraughty S
J Dermatol; 2019 Jun; 46(6):482-497. PubMed ID: 31062408
[TBL] [Abstract][Full Text] [Related]
15. The Role of IL-17 in the Pathogenesis of Psoriasis and Update on IL-17 Inhibitors for the Treatment of Plaque Psoriasis.
AbuHilal M; Walsh S; Shear N
J Cutan Med Surg; 2016 Nov; 20(6):509-516. PubMed ID: 27207350
[TBL] [Abstract][Full Text] [Related]
16. The role of IL-17 in psoriasis.
Malakouti M; Brown GE; Wang E; Koo J; Levin EC
J Dermatolog Treat; 2015 Feb; 26(1):41-4. PubMed ID: 24552504
[TBL] [Abstract][Full Text] [Related]
17. IL-17 and IL-17R: an auspicious therapeutic target for psoriatic disease.
Mitra A; Raychaudhuri SK; Raychaudhuri SP
Actas Dermosifiliogr; 2014 Oct; 105 Suppl 1():21-33. PubMed ID: 25398489
[TBL] [Abstract][Full Text] [Related]
18. Interleukin-17 (IL-17) inhibitors in the treatment of plaque psoriasis: a review.
Gooderham M; Posso-De Los Rios CJ; Rubio-Gomez GA; Papp K
Skin Therapy Lett; 2015; 20(1):1-5. PubMed ID: 25807214
[TBL] [Abstract][Full Text] [Related]
19. Novel Therapeutic Approaches and Targets for Treatment of Psoriasis.
Radi G; Campanati A; Diotallevi F; Bianchelli T; Offidani A
Curr Pharm Biotechnol; 2021; 22(1):7-31. PubMed ID: 32598253
[TBL] [Abstract][Full Text] [Related]
20. Anti IL-17 in psoriasis.
Ly K; Smith MP; Thibodeaux Q; Reddy V; Liao W; Bhutani T
Expert Rev Clin Immunol; 2019 Nov; 15(11):1185-1194. PubMed ID: 31603358
[No Abstract] [Full Text] [Related]
[Next] [New Search]
